Propiram fumarate

Shire is developing propiram (Dirame, under license from Bayer), a non-addictive analgesic for the relief of moderate-to-severe pain. It is intended for the management of cancer pain, traumatic and post-surgical pain, and pain associated with dental surgery and childbirth [201830]. Propiram is effective for the treatment of mild-to-moderate pain and is more active than codeine, while showing no addictive potential. In July 2001, Shire confirmed that the product was undergoing phase III trials and anticipated launch in its first market to take place in 2003 [317541], [415823]. In June 2001, ABN AMRO predicted launch in 2003 with sales of $16 million in 2003 rising to $24 million in 2005 [422762].

Several methods are used for the determination of LSD in forensic science casework samples. One of these involving a shift in UV absorption maximum is considered too nonspecific to provide unequivocal confirmation of the presence of LSD. Currently, HPLC methods using fluorescence detectors are recommended for quantification and capillary GC/MS is considered a good technique for the qualitative identification of the drug. In this work we demonstrate the possibility of using capillary GC for the quantitative determination of LSD since this method is equally sensitive but surely more flexible and rapid than the HPLC ones.